Japanese drugmaker Shionogi has sued Indian company Aurobindo Pharma in an attempt to stop it from producing the generic version of their drug Doribax. Aurobindo had filed for an abbreviated new drug application last year seeking FDA's go-ahead to ... Financial Chronicle, 5 days ago
TOKYO Dec 1 (Reuters) - Shionogi & Co Ltd : * Says to buy back up to 2.99 percent of own shares for as much as 30 billion yen FurtherReuters UK, 1 month ago
Ospemifene ( Senshio , Shionogi Limited) was recommended by a European Medicines Agency (EMA) panel for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are unable to use local vaginal estrogen ...American Journal of Public Health, 2 months ago CHMP nods several drugs through Pharmafocus, 2 months ago More November EMA/CHMP recommendations Pharma Letter, 2 months ago News and press releases: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 November 2014 European Medicines Agency, 2 months ago
Pharmaceutical company Mylan The company said the product is the first generic version of Shionogi's Orapred ODT, which is indicated as an anti-inflammatory or immunosuppressive agent for certain conditions; and also for the treatment of certain ...BusinessWeek, 1 month ago Mylan launches generic anti-inflammatory drug Individual.com, 1 month ago Mylan introduces generic Orapred ODT in US market PharmaBiz, 1 month ago Mylan Launches Generic Orapred ODT Monthly Prescribing Reference, 1 month ago
SHIONOGI : Data from Shionogi & Co. Ltd. Advance Knowledge in Solid Cancer (Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine...
Data from Shionogi & Co. Ltd. Advance Knowledge in Solid Cancer (Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours) By a News Reporter-Staff News Editor ...4 Traders, 2 days ago
Drug Name(s) PONSTEL FDA Application No. (NDA) 015034 Active Ingredient(s) MEFENAMIC ACID Company SHIONOGI INC Original Approval or Tentative Approval Date March 28, 1967 Chemical Type ...U.S. Food and Drug Administration, 2 weeks ago UPDATE 1-FDA approves BioCryst's intravenous flu drug CNBC, 1 month ago UPDATE 2-FDA approves BioCryst's intravenous flu drug Reuters UK, 1 month ago FDA approves BioCryst's intravenous flu drug Social Dashboard, 1 month ago
Rating and Investment Information, Inc. (R&I) has announced the following: The royalty income from hyperlipidemia treatment "Crestor", which has grown to the world's third by sales, supports the overall earnings of Shionogi & Co., Ltd. In order to ...Noodls, 1 month ago
/PRNewswire/ -- The Global Anxiety Disorders Market 2015-2019 research report, now available with ReportsnReports.com, says that in addition to emerging markets' focus, the key vendors are trying to penetrate the market by organizing awareness ...Town Hall, 3 days ago Global Anxiety Disorders Market 2015-2019 companiesandmarkets.com, 2 days ago
(Mumbai) - The Japanese equities index jumped close to one-month highs and closed higher cheering the newly-announced quantitative easing (QE) program by the ECB in the previous session. The benchmark Nikkei 225 index ended 1.05% higher at 17511.75 ...FXStreet.com, 2 days ago
KNIGHT THERAPEUTICS INC. ANNOUNCES BOARD CHANGE Hillel Rosen has resigned as a director of Knight Therapeutics Inc. The company has appointed Ed Schutter to Knight's board of directors. "Hillel will continue to provide legal counsel to Knight and ...Stockwatch, 4 days ago Knight Therapeutics Inc. : Announces Board Change 4 Traders, 4 days ago KNIGHT THERAPEUTICS : Announces Board Change 4 Traders, 4 days ago Knight Therapeutics Announces Board Change FirstWord Pharma, 4 days ago
on your WebpageAdd Widget >Get your members hooked!